AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05087381
Drug: Niclosamide Pill
RxNorm normalized name: niclosamide Pill
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs.
Trial: NCT05284448
Drug: pentoxifylline (Trental SR®)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg three times daily
Trial: NCT06580717
Drug: enavogliflozin 0.3mg
DrugBank: Enavogliflozin (DB18970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enavogliflozin 0.3mg, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo.
Trial: NCT05901441
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
Trial: NCT05901441
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
Trial: NCT05172817
Drug: Advixa (Adalimumab)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
Trial: NCT00134186
Drug: motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06425549
Drug: bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.
Trial: NCT06425549
Drug: ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.
Trial: NCT06084845
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06084845
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06084845
Drug: Xevinapant
RxNorm normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06106412
Drug: Ionomycin SIGMA
RxNorm normalized name: Monomycin A
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oocytes will be activated with Ionomycin SIGMA
Trial: NCT05569668
Drug: Paclitaxel- and platinum-based chemotherapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant Chemotherapy
Trial: NCT04717531
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg, qd, po, day 1-21
Trial: NCT04717531
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 mg/kg, day 1
Trial: NCT04717531
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 420 mg, day 1
Trial: NCT04717531
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m2, day 1
Trial: NCT04717531
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90mg/m2, day 1
Trial: NCT05865496
Drug: 611
RxNorm normalized name: T611
DrugBank: T611 (DB06391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 611 subcutaneous (SC) injection.
Trial: NCT05707468
Drug: ADT combined with abiraterone
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive long-term ADT combined with abiraterone.
Trial: NCT05621746
Drug: Esperoct
RxNorm normalized name: Esperoct
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
Trial: NCT05147402
Drug: midomafetamine
RxNorm normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl).
Trial: NCT05840211
Drug: Sacituzumab Govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT05840211
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05840211
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04871204
Drug: Octreotide Injection
RxNorm normalized name: octreotide Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg Sandostatin LAR intramuscular injection
Trial: NCT05758610
Drug: ETH-155008
RxNorm normalized name: ETH
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal.
Trial: NCT06640257
Drug: SHR-1314 injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1314 injection
Trial: NCT06261125
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will reveive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT.
Trial: NCT06261125
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily after the completion of SBRT.
Trial: NCT06431841
Drug: Atropine 0,025%
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine 0,025% (1 drop per day)
Trial: NCT06316232
Drug: MED ON plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of a 2x levodopa morning dose
Trial: NCT04866160
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583
Trial: NCT05342389
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a PD-1 antibody
Trial: NCT05342389
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an oral tyrosine kinase inhibitor
Trial: NCT05725291
Drug: AMT-116
RxNorm normalized name: Amtagvi
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05797935
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content
Trial: NCT05835011
Drug: Magrolimab
RxNorm normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration
Trial: NCT05708157
Drug: concomitant intranasal antihistamine and corticosteroid
RxNorm normalized name: Ahist Antihistamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: concomitant intranasal administration with antihistamine and corticosteroid
Trial: NCT05720715
Drug: cyclosporine A 0.05% eye drops
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.
Trial: NCT01386398
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01386398
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05287126
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
Trial: NCT05559801
Drug: Bone marrow-derived mesenchymal stromal cells (MSCs)
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.
Trial: NCT06482788
Drug: Adebrelimab (anti-PD-L1) + XELOX
RxNorm normalized name: ethanol
DrugBank: Adebrelimab (DB16412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adebrelimab: 1200mg, i.v., each infusion lasts 30-60 minutes and is administered on the first day of each cycle (3 weeks).~Capecitabine: 1000mg/m2 , bid, orally, from day 1 to day 14 of each cycle (3 weeks).~Oxaliplatin: 130mg/m2, i.v., each infusion is administered on the first day of each cycle (3 weeks).
Trial: NCT04807309
Drug: Danazol Pill
RxNorm normalized name: danazol Pill
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 200 mg orally twice a day
Trial: NCT06015074
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
Trial: NCT06015074
Drug: Ciprofol
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
Trial: NCT04817345
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous
Trial: NCT06140758
Drug: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice
RxNorm normalized name: sodium fluoride
DrugBank: Rice (DB10563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Trial: NCT06140758
Drug: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice
RxNorm normalized name: Colgate
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Trial: NCT06140758
Drug: Toms of Maine 0 ppm Fluoride Dentifrice
RxNorm normalized name: sodium fluoride
DrugBank: Rice (DB10563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Trial: NCT06140758
Drug: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice
RxNorm normalized name: sodium fluoride Mouthwash [Colgate]
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Trial: NCT06140758
Drug: 1100 ppm (0.454% Stannous fluoride) Dentifrice
RxNorm normalized name: sodium fluoride
DrugBank: Rice (DB10563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Trial: NCT06458036
Drug: Selpercatinib Monotherapy
DrugBank: Selpercatinib (DB15685)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive selpercatinib monotherapy for 6 months at the FDA-approved dose.
Trial: NCT05924425
Drug: Daridorexant 50 mg
RxNorm normalized name: daridorexant 50 MG
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized in the experimental group will receive the treatment every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
Trial: NCT06648200
Drug: JS004
RxNorm normalized name: Immunoglobulin g4, anti-(human b and t lymphocyte attenuator (btla)) (human-mus musculus monoclonal js004 .gamma.4-chain), disulfide with human-mus musculus monoclonal js004 .kappa.-chain, dimer
DrugBank: Tifcemalimab (DB18914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days.
Trial: NCT06648200
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days.
Trial: NCT06648200
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days.
Trial: NCT06648200
Drug: Platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days.
Trial: NCT05334485
Drug: Pyridostigmine Bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 60mg pyridostigmine bromide
Trial: NCT05214183
Drug: Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
Trial: NCT05839197
Drug: Camrelizumab plus Apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib(250 mg; p.o.; qd.); camrelizumab (200 mg; iv drip; q3w) If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC.
Trial: NCT06683066
Drug: Triprorelin for injection
RxNorm normalized name: triptorelin Injection
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specification: Triprorelin for injection 3.75mg. Produced and supplied by Qilu Pharmaceutical Co.
Trial: NCT06683066
Drug: Diphereline
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specification: Diphereline 3.75mg. Produced by Ipsen Pharma Biotech and supplied by Qilu Pharmaceutical Co.
Trial: NCT00002086
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002086
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002086
Drug: Interferon alfa-n1
RxNorm normalized name: interferon alfa-n1
DrugBank: Interferon alfa-n1 (DB00011)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06252493
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon will be injected into the subject's indwelling i.v. catheter (0.3-0.5 mg) before imaging acquisition; or intramuscularly (1-2 mg) prior to imaging the abdomen and pelvis. A second administration of IV glucagon (0.3-0.5mg) may take place during image acquisition.
Trial: NCT06160895
Drug: TQ-A3334 tablets
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
Trial: NCT06685081
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine was injected in dose of 0.25 µg/kg
Trial: NCT06685081
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine was injected in dose of 0.5 µg/kg
Trial: NCT06685081
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine was injected in dose of 0.75 µg/kg
Trial: NCT06685081
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine was injected in dose of 1 µg/kg
Trial: NCT06685081
Drug: lidocaine and triamcinolone
RxNorm normalized name: lidocaine / triamcinolone
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection
Trial: NCT06580301
Drug: YK012
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.
Trial: NCT06683885
Drug: Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For non GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Obutinib, 150mg, QD, P.O.; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Obutinib maintain treatment for 6 months. Obutinib, 150mg, QD, P.O. After 6 cycles of initial treatment, the efficacy was evaluated.~For GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Decitabine, 10mg, QD，D1-5, ivgtt; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Decitabine maintenance treatment for 4 cycles, 21 days per cycle. Decitabine, 10mg, QD，D1-5, ivgtt. Evaluate the efficacy after 6 cycles of treatment.
Trial: NCT05879523
Drug: HRS-1893
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, single dose, multiple doses
Trial: NCT06251635
Drug: Olanzapine 2.5Mg Oral Tablet
RxNorm normalized name: Olanzapine 2.5mg Oral tablet
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine capsules (2.5mg) will be administered during one research visit for each menstrual cycle phase. The dosing schedule is as follows:~1. Day 0- 5mg~2. Day 1- 10mg
Trial: NCT06251635
Drug: Insulin Lispro 100 UNT/ML
RxNorm normalized name: insulin lispro 100 UNT/ML
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At each visit, participants will be given an intranasal insulin challenge (160 IU) to assess brain insulin signalling via MRI based assay.
Trial: NCT06251635
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At each visit, participants will be given an intranasal saline placebo (1.6 mL) in order to establish baseline brain insulin signalling via MRI based assay.
Trial: NCT05628038
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w
Trial: NCT05628038
Drug: folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 q2w